News

FDA clears Lumvoa for active and chronic thyroid eye disease, offering rapid proptosis and diplopia gains—plus key safety monitoring tips.

Canto-Sims, OD, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care.

Erin Rueff, OD, PhD, FAAO, provides an introduction to Johnson & Johnson's versatile contact lens family.

Jacqueline Theis, OD, FAAO, underscored the importance of individualizing care based on where the patient is in their MS journey.

Mark Schaeffer, OD, FAAO, stated that optometrists should be prepared for even the rarest cases of emergencies and urgencies.

ZEISS partners with Envision to expand evidence-backed VR perimetry, enabling more accessible, gamified home visual field testing for glaucoma monitoring.

The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.

Raman Bhakhri, OD, FAAO, outlines the biomarkers that optometrists should keep in their wheelhouse when examining patients.

Melody Tavakoli, OD, stated that patient complicance remains one of the biggest challenges for contact lens wearers.

Lori-Ann Christie, PhD, detailed a poster presentation titled "Comparative Analysis of AREDS2 and AREDS2+B Vitamin Complex in an in vitro Model of Age-Related Macular Degeneration."

Will eye drops be an option in the future for keratoconic patients? Clark Chang, OD, MSA, MSc, FAAO, gave us the run-down of what active research may make possible.

Preservative-free bimatoprost gel now offers once-daily glaucoma and ocular hypertension IOP reduction, aiming to boost comfort, tolerability, and long-term adherence.

Mile Brujic, OD, FAAO, stated in a poster presentation that a multi-practice study found that the lens had particularly positive effects on patients who reported dryness symptoms.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, details the challenges of managing dry eye in contact lens wearers via accurate diagnosis and thoughtful lens fitting.

Mitch Ibach, OD, FAAO, said that medication optimization is key when taking the interventional approach to glaucoma.

The emerging technology offers a new paradigm for treating a group of eye diseases.

Joe Shovlin, OD, FAAO, outlines the management and treatment of corneal infections in one of his Optometry's Meeting presentations.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, discussed his AOA 2026 presentation "Eye of the Needle Returns: Navigating the Patient’s Journey Receiving Intravitreal Injections."

A cross-sectional study of nearly 10,000 nursing home residents found a clear dose-response relationship between vision loss and cognitive impairment, with blind residents having nearly 3 times the odds of cognitive loss compared with those with normal vision.

A Johnson & Johnson Vision poster found a novel multifocal toric daily disposable contact lens delivered visual acuity within 1 letter and comparable fitting success to an existing nontoric multifocal lens, extending coverage to presbyopes with up to 1.75D astigmatism.

Melody Tavakoli, OD, said that she has found that workhorse in Johnson & Johnson's Oasys lens family.

A systematic review of 22 studies found Demodex infestation strongly associated with MGD, with MGD prevalence reaching 92% to 99% in symptomatic Demodex blepharitis and significantly worse meibomian gland structure and function in infested patients.

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, myopia management is best started sooner rather than later.

A real-world pilot across 8 optometric sites found Qlosi (0.4% pilocarpine) implementation met or exceeded all corporate KPIs, with UWF imaging utilization rising 16.4 percentage points and 72.7% of patients achieving personal treatment goals.

GATHER2 OLE data through 3.5 years show avacincaptad pegol reduced GA lesion growth by 28.8% in continuously treated patients and 37% to 40% in those switched from sham, with no new safety signals.

Anna Tichenor, OD, PhD, FAAO, details her poster – one of AOA 2026's Top Five posters – that identified how quickly and how meaningfully patients experience symptom improvement, and which types of symptoms are affected.

A retrospective study of 27 dry eye patients found adjunctive preservative-free periocular skincare significantly reduced periocular erythema and MGD severity over 28 days, with 93% of patients reporting intent to continue use.

A VA case report documents rapid PDR progression to intravitreal anti-VEGF treatment in a patient 6 months after semaglutide initiation, reinforcing AOA monitoring guidance for GLP-1 patients with preexisting DR.